Randomized Study of Letrozole and Trilostane for Medical Abortion
NCT ID: NCT01615211
Last Updated: 2015-05-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
36 participants
INTERVENTIONAL
2012-05-31
2013-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study on Combined Use of Letrozole, Mifepristone and Misoprostol in Termination of Pregnancy
NCT01475318
Comparison Between Letrozole and Mifepristone in Medical Termination of First Trimester Miscarriages
NCT05304273
Repeated Doses of Misoprostol for Medical Treatment of Missed Miscarriage
NCT01615224
Letrozole Pretreatment With Misoprostol Induction of Abortion In First-Trimester Missed Miscarriage
NCT04215835
Letrozole Pretreatment With Misoprostol for Second-Trimester Medical Abortion
NCT02405156
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard treatment
patients will receive standard treatment with 200mg Mifepristone and after 36-48 hours 800 mcg of misoprostol vaginally
No interventions assigned to this group
trilostane
patients will receive Day 1: Mifepristone 200 mg and Trilostane 120mg 1 tablet twice and Day 2 Trilostane 240mg twice. On Day 3 800 mcg misoprostol will be given vaginally.
Trilostane
Day 1 Trilostane 120mg twice and Day 2 Trilostane 240mg twice
Letrozole
Patients will receive on Day 1 Mifepristone 200mg and Letrozole 2,5mg 3 tablets and on Day 2 Letrozole 2,5mg 3 tablets. On day 3 800mcg of misoprostol will be given vaginally
Letrozole
Day 1 Letrozole 2,5mg 3 tablets Day 2 Letrozole 2,5mg 3 tablets
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Letrozole
Day 1 Letrozole 2,5mg 3 tablets Day 2 Letrozole 2,5mg 3 tablets
Trilostane
Day 1 Trilostane 120mg twice and Day 2 Trilostane 240mg twice
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Karolinska Institutet
OTHER
The University of Hong Kong
OTHER
Kristina Gemzell Danielsson
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kristina Gemzell Danielsson
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kristina Gemzell Danielsson, professor
Role: PRINCIPAL_INVESTIGATOR
Karolinska Institutet
Helena Kopp Kallner, MD
Role: PRINCIPAL_INVESTIGATOR
Karolinska Institutet
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Karolinska University Hospital
Stockholm, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
W300TL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.